![]() |
MDL-800
- 英文名称:MDL-800
- 品牌:WYTSCI
- 产地:进口
- 型号:1MG
- 货号:WT-AY-B11204
- cas:2275619-53-7
- 价格: ¥1/mg
- 发布日期: 2025-04-10
- 更新日期: 2025-05-23
产品详请
产地 | 进口 |
品牌 | WYTSCI |
货号 | WT-AY-B11204 |
用途 | 科研检测 |
英文名称 | MDL-800 |
包装规格 | 1MG |
CAS编号 | 2275619-53-7 |
别名 | MDL-800 |
纯度 | 98+% |
分子式 | |
是否进口 | 是 |
纯度:98% by HPLC;NMR (Conforms)
分子式:C21H16BrCl2FN2O6S2
分子量:626.29
溶剂:DMSO (up to at least 10 mg/ml with warming)
性状:White solid
存储:-20°C
Activity (short version):SIRT6 activator
Function / Pharmacology:Allosteric activator of SIRT6 (EC50 = 10.3 μM).1 It specifically activates the deacetylase (H3K9ac and H3K56ac) activity of SIRT6 – inactive against SIRT1,3,4 and HDACs 1-11 with 10x less activity against SIRT2,5,7. It inhibited the growth of human hepatocarcinoma cells (HCC) via the tumor suppressor deacetylase (H3K9ac and H3K56ac) via cell-cycle arrest and showed efficacy in a xenograft model of HCC. MDL-800 improved the genetic stability of old-murine-derived iPSCs via activation of NHEJ and BER DNA repair pathways suggesting promise in treating age-related diseases via iPSC-based therapies.2 MDL-800 inhibited the proliferation of 12 non-small cell lung carcinoma cell lines with IC50 values of 21.5 to 34.5 μM.3 It also enhanced the effects of EGFR kinase inhibitors in Osimertinib-resistant HCC827 and PC9 cells as well as in patient-derived primary tumor cells.3
分子式:C21H16BrCl2FN2O6S2
分子量:626.29
溶剂:DMSO (up to at least 10 mg/ml with warming)
性状:White solid
存储:-20°C
Activity (short version):SIRT6 activator
Function / Pharmacology:Allosteric activator of SIRT6 (EC50 = 10.3 μM).1 It specifically activates the deacetylase (H3K9ac and H3K56ac) activity of SIRT6 – inactive against SIRT1,3,4 and HDACs 1-11 with 10x less activity against SIRT2,5,7. It inhibited the growth of human hepatocarcinoma cells (HCC) via the tumor suppressor deacetylase (H3K9ac and H3K56ac) via cell-cycle arrest and showed efficacy in a xenograft model of HCC. MDL-800 improved the genetic stability of old-murine-derived iPSCs via activation of NHEJ and BER DNA repair pathways suggesting promise in treating age-related diseases via iPSC-based therapies.2 MDL-800 inhibited the proliferation of 12 non-small cell lung carcinoma cell lines with IC50 values of 21.5 to 34.5 μM.3 It also enhanced the effects of EGFR kinase inhibitors in Osimertinib-resistant HCC827 and PC9 cells as well as in patient-derived primary tumor cells.3